Shareholders of BRAIN Biotech AG approved all agenda items with a broad majority at the company's 2026 Annual General Meeting for the 2024/25 financial year. Dr. Ursula La Cognata of Berlin, managing partner of ybe (Your Biotech Experts Partnership), was elected to the Supervisory Board for a four-year term. She had previously been appointed by the Darmstadt Local Court as a new member effective July 11, 2025, until the next Annual General Meeting.
In his statement to shareholders, Supervisory Board Chairman Dr. Michael Majerus expressed confidence in the company's development opportunities. "We remain convinced that BRAIN Biotech AG has many positive development opportunities thanks to its successful product business, its strong market position in contract research, the expected revenues from the monetization initiatives as well as licensing of pharmaceutical projects, and further product innovations from the BRAINBioIncubator," Majerus stated. This outlook underscores the strategic importance of the company's diversified approach to growth and innovation in the specialty enzymes market.
CEO Adriaan Moelker addressed the company's strategic direction during the meeting, emphasizing the effectiveness of BRAIN Biotech's two-pillar approach. "We remain convinced that our two-pillar strategy, with the product-oriented BRAINBiocatalysts segment on the one hand and the BRAINBioIncubator segment on the other, is the right strategy," Moelker said. He explained that this approach enables the company to monetize investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business while offering customers unique selling points. The strategy's significance lies in its dual focus on immediate commercial returns through established products and long-term value creation via research and development incubator projects.
Moelker highlighted the company's agility as a significant competitive advantage, noting that BRAIN Biotech's relatively small size allows for quick and flexible responses to customer needs through short communication channels. The CEO emphasized the importance of maintaining this advantage even as the company experiences stronger future growth. Moelker also reported on operational developments, including the consolidation of production and sales for enzymes and food ingredients for the baking and beverage industries at a new location in the Netherlands. The new facility, which will house a modern baking application center, laboratory, and production areas, is nearing completion. This operational consolidation is crucial for enhancing efficiency and supporting the company's market position in key industry segments.
A total of 61.82% of the share capital, including postal votes, was represented at the time of voting. The detailed voting results and all other documents relating to the 2026 Annual General Meeting are available on the BRAIN Biotech AG website. The company operates as a leader in researching, developing, and producing specialty enzymes with a focus on the food and life sciences industries. BRAIN Biotech AG has been listed on the Frankfurt Stock Exchange since February 9, 2016, and generated revenue of €49.6 million with approximately 280 employees during the 2024/25 fiscal year. The shareholder approval and strategic reaffirmations at the meeting signal stability and forward momentum for the company, reinforcing its commitment to leveraging enzymatic solutions for industrial applications.
